Related Experiment Video

Updated: Aug 11, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Designing clinical trials for kidney cancer based on newly developed prognostic and predictive tools

Daniel Cho1, David McDermott, Michael Atkins

  • 1Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.

Current Urology Reports
|February 17, 2006
PubMed

Insights

Advances in understanding renal cell carcinoma molecular aberrations have identified new biomarkers for prognosis and treatment. Integrating these markers into clinical trials is crucial for developing personalized therapies for advanced renal cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Trials

Background:

  • Significant progress in understanding molecular aberrations in renal cell carcinoma (RCC).
  • Identification of novel prognostic and predictive biomarkers for RCC.
  • Development of novel therapeutic agents targeting specific molecular pathways in advanced RCC.

Purpose of the Study:

  • To emphasize the importance of integrating novel prognostic and predictive markers into clinical trial design for RCC.
  • To advocate for the combination of novel markers with traditional prognostic features for improved prognostic models.
  • To highlight the necessity of prospective validation of these markers and models in clinical trials.

Main Methods:

  • Review of recent advances in RCC molecular biology and targeted therapies.
  • Analysis of current clinical trial designs and their integration of biomarkers.
  • Discussion of strategies for developing robust prognostic models and prospective validation.

Main Results:

  • Novel molecular aberrations in RCC have yielded promising prognostic and predictive biomarkers.
  • Emerging targeted agents show efficacy in advanced RCC therapy.
  • Integration of biomarkers into clinical trials can enhance prognostic accuracy and therapeutic guidance.

Conclusions:

  • Prospective validation of prognostic models and predictive markers is essential.
  • Validated biomarkers and models will enable personalized therapy selection for RCC patients.
  • This approach will optimize treatment strategies based on individual patient characteristics.

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...